Develops innovative small-molecule therapies for autoimmune diseases and cancer, focusing on effective oral treatments and collaborative partnerships to improve patient outcomes.
VentureRadar Research / Company Website

Lead Pharma is a spinoff from the prestigious Hubrecht Institute and the University Medical Center Utrecht. Lead Pharma’s strengths in innovation rely on a powerful discovery engine that is based on comprehensive in-house capabilities and an integrated suite of cutting-edge technologies. We develop innovative small-molecule therapies for patients with autoimmune disease or cancer. We are developing a pipeline of small-molecule drugs to treat autoimmune diseases and cancer. We have programs for ROR?t, ERRa, LXR, PRMT5, TH17.
VentureRadar Research / Company Website

Associated sectors:
Therapeutics and nutraceuticals for human application; Biotechnology; autoimmune diseases; Cancer; small molecule drugs; Pharmaceutical; Biotech; Healthtech; Life Sciences; Small Molecule Pharmaceuticals;

Similar Companies:

Karus Therapeutics

United Kingdom

Privately Held

Karus Therapeutics is a leader in the development of innovative medicines that have breakthrough potential in treating inflammatory disease and cancer. The Company's scientific excellence is reflected in its proprietary PI3K and HDAC6 inhibitor programmes, from which innovative small molecule drugs with significant clinical and commercial potential have been developed. The UK based Company is privately-held with a strong financial track record and experienced investors, including SV Life Sciences, New Leaf Ventures, Novo A/S and IP Group.

INNOVIMMUNE BIOTHERAPEUTICS, INC.

USA

Privately Held

Innovimmune Biotherapeutics is a specialty Drug Discovery & Exploratory Development biotechnology company leading the development of novel first-in-class and best-in-class proprietary small molecule NME immunomodulatory drugs for the treatment of Autoimmune & Immuno-Inflammatory Diseases and Cancer. The company has programs for: FXR Agonist for Hepatology; LXR Agonist for Immuno-Oncology & Atopic Dermatitis; ROR Gamma Agonist for Immuno-Oncology; MIF Inhibitor for Autoimmune Diseases & Immuno-Oncology; ROR Gamma Inverse Agonist for Autoimmune & Immuno-Inflammatory Diseases.

4SC

Germany

Publicly Traded

4SC focuses on the development of novel small molecule drugs that target key mechanisms of cancer development, such as histone deacetylases (HDAC). Such drugs are intended to provide patients with innovative treatment options that are more tolerable and efficacious than existing therapies and provide a better quality of life. 4SC’s current product pipeline includes two programs in clinical development: resminostat and domatinostat. 4SC’s goal is to advance its own drug development programs in order to increase the value of the Company as a whole through entering into valuable partnerships with pharmaceutical and biotechnology companies for the further development or commercialization of 4SC’s drug candidates, and/or the eventual marketing and sales of approved drugs in select territories, such as Europe.

858 Therapeutics

USA

Privately Held

858 Therapeutics is a biotechnology and drug discovery company developing a portfolio of small molecule drugs that act on novel therapeutic targets in oncology, including proteins that regulate RNA and the innate immune response. 858 was founded by a veteran team who together bring a track record of success in pharma and biotech drug discovery. Building from our collective experience in the fields of epigenetics, single cell genomics, and innate immunity, 858 scientists are dedicated to the company’s mission to discover innovative therapeutics for the treatment of cancers that are resistant to current therapies.

Immunic Inc.

USA

Publicly Traded

Immunic is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. Immunic is developing three small molecule products: lead development program, vidofludimus calcium (IMU-838), a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn’s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor ROR?t, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.

Sareum

United Kingdom

Publicly Traded

Sareum discovers and develops innovative drug candidates aimed at cancers and autoimmune diseases. Our drug development programmes aim to improve outcomes for patients with serious medical conditions and where current therapies are inadequate. Sareum's most advanced development programme (Chk1) was developed in collaboration with the Institute of Cancer Research and the CRT Pioneer Fund. It is undergoing two Phase 2 clinical trials, being conducted by licence partner Sierra Oncology, with a further two trials planned. The other development programmes (TYK2/JAK1 Autoimmune, TYK2/JAK1 Cancer, Aurora+FLT3) are in preclinical development.